company background image
MAP

Microba Life Sciences ASX:MAP Stock Report

Last Price

AU$0.20

Market Cap

AU$54.9m

7D

0%

1Y

n/a

Updated

24 Sep, 2022

Data

Company Financials +
MAP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MAP Stock Overview

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States.

Microba Life Sciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Microba Life Sciences
Historical stock prices
Current Share PriceAU$0.20
52 Week HighAU$0.45
52 Week LowAU$0.19
Beta0
1 Month Change-4.76%
3 Month Change-27.27%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-42.86%

Recent News & Updates

Jul 05
Is Microba Life Sciences (ASX:MAP) In A Good Position To Invest In Growth?

Is Microba Life Sciences (ASX:MAP) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

MAPAU HealthcareAU Market
7D0%-4.6%-2.7%
1Yn/a-20.7%-11.0%

Return vs Industry: Insufficient data to determine how MAP performed against the Australian Healthcare industry.

Return vs Market: Insufficient data to determine how MAP performed against the Australian Market.

Price Volatility

Is MAP's price volatile compared to industry and market?
MAP volatility
MAP Average Weekly Movement14.6%
Healthcare Industry Average Movement5.2%
Market Average Movement9.6%
10% most volatile stocks in AU Market16.9%
10% least volatile stocks in AU Market4.3%

Stable Share Price: MAP is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: Insufficient data to determine MAP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aLuke Reidhttps://microba.com

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.

Microba Life Sciences Limited Fundamentals Summary

How do Microba Life Sciences's earnings and revenue compare to its market cap?
MAP fundamental statistics
Market CapAU$54.87m
Earnings (TTM)-AU$11.47m
Revenue (TTM)AU$4.69m

11.7x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MAP income statement (TTM)
RevenueAU$4.69m
Cost of RevenueAU$2.32m
Gross ProfitAU$2.37m
Other ExpensesAU$13.84m
Earnings-AU$11.47m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.042
Gross Margin50.46%
Net Profit Margin-244.64%
Debt/Equity Ratio1.1%

How did MAP perform over the long term?

See historical performance and comparison